The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Bifunctional anti-PD-L1/TGF-ßRII agent SHR-1701 plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Survival results of a phase II trial.
 
Yi Wang
No Relationships to Disclose
 
Hong Liu
No Relationships to Disclose
 
Qingwei Wang
No Relationships to Disclose
 
Naian Qiao
No Relationships to Disclose
 
Jianbo Wang
No Relationships to Disclose
 
Bingxu Tan
No Relationships to Disclose
 
Bo Cheng
No Relationships to Disclose
 
Yunxia Chu
No Relationships to Disclose
 
Changhong Zhao
Employment - Jiangsu Hengrui Pharmaceuticals
 
Xiaoyu Chen
Employment - Jiangsu Hengrui Pharmaceuticals
 
Yufeng Cheng
No Relationships to Disclose